TORONTO, June 15 /CNW/ - Amorfix Life Sciences (TSX-V:AMF), a company focused on diagnostics and treatments for brain wasting diseases, today announced that it has achieved ISO13485:2003 certification for its in vitro diagnostic EP-vCJDTM test for detection of aggregated misfolded proteins in variant Creutzfeldt-Jacob Disease (vCJD).
